Beyond blood pressure: the endothelium and atherosclerosis progression (Q34970381)

5 August 2017

1 reference

title

Beyond blood pressure: the endothelium and atherosclerosis progression (English)

1 reference

5 August 2017

0 references

1 reference

Ernesto L Schiffrin

1

1 reference

PubMed ID

12383592

5 August 2017

Canadian Institutes of Health Research Multidisciplinary Research Group on Hypertension

series ordinal

2

1 reference

5 August 2017

1 October 2002

1 reference

Journal of Clinical Hypertension

5 August 2017

1 reference

5 August 2017

15

1 reference

5 August 2017

10 Pt 2

1 reference

5 August 2017

115S-122S

1 reference

Endothelial function as a determinant of vascular function and structure: a new therapeutic target

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Is high blood pressure a late manifestation of the hypertension syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Matrix metalloproteinases and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Molecular bases of the acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Angiotensin II type 1 receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

7 January 2021

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

7 January 2021

Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

7 January 2021

In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

7 January 2021

Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

7 January 2021

Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0895-7061%2802%2903006-6

7 January 2021

10.1016/S0895-7061(02)03006-6

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12383592